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Abstract












Multiple myeloma (MM) is a malignancy of plasma cells which accumulate in the bone marrow, causing clinical symptoms as a consequence of myelosuppression, osteolysis and the production of monoclonal protein 1. Although current first line therapies in MM are diverse, high-dose therapy (HDT) followed by autologous stem cell transplantation (ASCT) remains a standard treatment for newly diagnosed myeloma patients who are considered to be able to tolerate the procedure. Compared to prior standard treatments it has been shown to increase the median overall survival (OS) by a year to 4-5 years  ADDIN EN.CITE 2-3. The introduction of novel agents as part of induction and maintenance has improved outcomes further  ADDIN EN.CITE 4-6. However, virtually all transplant patients eventually relapse, and the duration of remission is highly variable ranging from a few months to more than 10 years. The difference in outcome is thought to be mediated via tumour acquired genetic differences  ADDIN EN.CITE 7. A diagnostic test able to identify patients at high risk of early relapse based on such genetic differences would be of great clinical utility as it would allow clinicians to design and implement trials investigating new therapeutic strategies in this high risk subset. Any test used in such a setting should have high specificity for the correct identification of high risk behaviour as well as having good sensitivity to be able to identify such cases. 
Until now a number of approaches have been used to determine risk status.  The initial approach used Beta-2-microglobulin (β2M) level which was subsequently incorporated into the international staging system (ISS)  ADDIN EN.CITE 8.  While the ISS is generally applicable, it works best for classifying populations entered into clinical trials and lacks biological relevance. Genetic variables associated with poor outcome have been identified, fluorescence in situ hybridization (FISH) studies have identified the presence of del(17p13), gain(1q21), del(1p) as well as adverse translocations t(4;14), t(14;16) and t(14;20) as high risk factors  ADDIN EN.CITE 9-13. However, despite the fact that this approach can identify distinct biological groups, the sensitivity and specificity for identifying high risk behaviour are too poor to be used as a diagnostic tool, and developing alternative approaches is a priority to reliably identify high risk patients. 




MRC Myeloma IX trial  (ISRCTN68454111) enrolled 1960 newly diagnosed symptomatic myeloma patients, who were allocated to two main treatment pathways, intensive (N= 1111) or non-intensive (N=849), at the discretion of the treating physician taking account of the age and performance status 4. For the purpose of reliably defining early relapse subjects following HDT procedure, cases used in this study were all based on per protocol rather than intention to treat. Of the 1111 patients in the intensive arm, 747 cases who actually received HDT were used for subsequently analyses (Figure S1A). Early/late relapse subgroups were defined by calculating the duration from the time of HDT to subsequent relapse. 
Gene expression profiles from CD138-selected bone marrow plasma cells (to a purity of more than 90%) of 261 patients from Myeloma IX (GSE15695) were collected as previously described 17.  In addition two other similar publicly available gene expression sets were used in this study for development of a GEP-based predictor. 97 evaluable cases from Myeloma IX  and 82 evaluable cases from HOVON65 (GSE19784, ISRCTN64455289)  ADDIN EN.CITE 18 being treated with single HDT were combined to form a training set of 179 samples, and batch effect was removed using Bioconductor package Combat 19. In general, cases that died from reasons other than progressive myeloma (mostly other cancers, heart disease, stroke and infection) within 1 year post-HDT were excluded, as the relapse status at 1 year post-HDT couldn’t be assessed. As there was partial overlap of samples between HOVON65 and GMMG-HD4 datasets, the subjects present in both datasets were excluded from the training set to ensure the independence of the test set. Following the same selection criteria 155 patients from GMMG-HD3/HD4 Trial (E-MTAB-362, ISRCTN06413384) 20, of which 56% were treated with double HDT, were used as a validation set for the GEP-based predictor. A summary of samples used in this study, therapy schedule and analysis flow is outlined in Figure S1B. The detailed designs of these trials have been reported previously  ADDIN EN.CITE 4, 6, 21. A further independent dataset (GSE24080) was used to validate its effect on PFS and OS.
Genes identified as being differentially expressed were correlated with matching SNP-based mapping (N=99) and DNA methylation profiling (N=118) data from Myeloma IX trial to explore possible mechanisms underlying deregulation. 

Bioinformatics and statistical Analysis
The gene expression profiles (GEPs) of all the samples from training and test sets were carried out on Affymetrix Human Genome U133 Plus 2.0 platform, gene expression signals were quantified using Robust Multi-array Average (RMA) normalization. All analyses were performed in R 2.10.1 and Bioconductor. Differentially expressed genes between patient groups were selected using significance analysis of microarray (SAM) (Bioconductor package samr) with a 1000-permutation adjustment. The LASSO algorithm (Bioconductor package glmnet) was used to further refine the selection to a subset of non-correlated genes with strongest discriminative power for early relapse. The selected genes were fitted in a logistic regression model to obtain an optimal model, and a risk score (z) for early relapse was calculated by a linear combination of the expression levels of the 17 selected genes at presentation, weighted by their estimated regression coefficients; subsequently the probability for early relapse can be calculated accordingly (Table 3). The predictive power (sensitivity/specificity) of a model was tested using a Receiver Operating Characteristic (ROC) method and corresponding Area Under Curves (AUCs) were calculated, which can be interpreted as the chance of getting the prediction correct. 
The associations between early and late relapse groups and various clinical parameters were investigated using Fisher’s exact test for categorical parameters and Wilcoxon test for continuous variables. Any parameters statistically associated with early relapse were combined in a multivariate logistic regression model to test their independence. Performance of the predictive models was compared using the likelihood-ratio test (R package anova.glm). Either Wilcoxon or Kruskal-Wallis test was used to correlate gene expression level and SNP-mapping as well as DNA methylation data where appropriate. As the impact of DNA methylation on gene expression is thought to result from a discrete methylation pattern (hyper- or hypo-methylation), we used the unsupervised k-means method to define the high/low methylation groups for each gene. The binary distribution of promoter methylation of the genes was visualized by Kernal density plot. The distribution of OS and PFS between risk groups was estimated using the Kaplan-Meier method (log-rank test). The performance of the derived high-risk gene signature (REL-17) was compared with another gene signature using multivariate logistic/Cox regression analysis. Pathway analyses were performed using GeneGo’s MetaCore (www.genego.com).

RESULTS
Defining a patient group with high risk clinical behaviour following HDT 
In order to identify a group of patients that have poor outcome post-HDT, 423 out of the 747 patients from Myeloma IX, who relapsed after HDT, were split into subgroups based on time to progression. The results show that patients who relapsed within 6 months and those who relapsed between 6 months and 1 year had significantly shorter post-relapse survival compared to the others (Figure 1A). When combined, these cases had a median post-relapse survival of 14.9 months in contrast to 40 months for those who relapsed after 1 year (Figure 1B, log-rank test p = 8.03x10-14), suggesting that they may represent two biologically distinct groups. 

Clinical and FISH parameters associated with high risk behaviour
Among the 747 patients treated with upfront HDT, relapse status at 1 year post-HDT was available in 718 cases, among which 18.2% (131 out of 718) relapsed within 1 year post-HDT. In order to compare the associated clinical and FISH parameters of this group with the rest of cases (N= 587), univariate logistic regression analyses were performed on parameters including gender, age, WHO performance status, haemoglobin (Hb), platelets (Plt), albumin (Alb), β2M, creatinine (Cr), calcium (Ca), Lactate dehydrogenase (LDH) and C-reactive protein (CRP), paraprotein type (IgA vs non-IgA), light chain type, duration from diagnosis to HDT, type of induction therapy, thalidomide maintenance, adverse IgH translocations (including t(4;14), t(14;16) and t(14;20)), del(17p), gain(1q) and del(1p). The results show that only low Hb, low Plt, presence of adverse IgH translocations and gain(1q) at presentation were statistically associated with early relapse (p < 0.05). When tested together in a multivariate logistic regression model, only adverse IgH translocations and gain(1q) retained statistical significance (Table 1). A predictor for early relapse was developed based on these two FISH abnormalities, but this only had modest predictive power (AUC 0.72 in the whole Myeloma IX dataset and 0.69 in both expression training and test datasets, Figure S2) and therefore was discarded. 

Development of a GEP-based predictor for early relapse
We have investigated whether a GEP-derived predictor could improve or outperform the FISH-based predictor. Among the 179 patients in the training set 22.3% (40 patients) relapsed within 1 year post-HDT, which is comparable to the complete dataset. The GEP of these two groups of patients was compared using significance analysis of microarray (SAM)  ADDIN EN.CITE 22, and 207 genes were identified as being differentially expressed at 5% false discovery rate (FDR), among which 173 were upregulated in early relapsed patients and 34 were down-regulated (Table S1). Gene enrichment analysis by chromosome location showed that there was a significant overrepresentation of genes from chromosome 1 and X (p < 0.001, Table S2). Fifteen of the 173 upregulated genes span a region corresponding to 1q21-q23, which might reflect the poor outcome associated with gain(1q) by FISH. Notably WHSC1, FGFR3 and MAF were among the top differentially expressed genes, known to be deregulated via t(4;14) translocation and t(14;16) respectively. 
In order to develop a robust yet manageable GEP-based predictor for early relapse, we repeated the analysis with a more stringent FDR of 0% and obtained 37 differentially expressed genes, among which 30 were upregulated in early relapsed patients while 7 were downregulated (Table 2). The 37 genes still show marked overrepresentation of genes from chromosome X (p = 0.0001), while the overrepresentation of genes from chromosome 1 was no longer seen. Among these 37 genes pathway analyses identified significant enrichment of epigenetic regulators including genes involved in histone modification (WHSC1, HIST1H4H) as well as other chromatin modificators NAP1L3 and HMGN5 (p < 0.05, adjusted for Benjamini-Hochberg multiple testing). Notably 6 of the top deregulated genes (NUDT11, PKP2, ROBO1, AGAP1, NAP1L3 and EPDR1) were recently identified as “stem cell” genes in myeloma 23. 
Each gene’s expression values were dichotomised, using the 75th percentile as a threshold between high and low expression for the upregulated genes and the 25th percentile as a threshold for the downregulated genes. These genes underwent further shrinkage and selection using the LASSO algorithm 24 yielding 17 genes with the strongest discriminative power for early relapse. The selected genes were fitted in a logistic regression model to generate an optimal gene-expression based predictor for likelihood of relapse within 1 year post-HDT (Table 3). 
The 17-gene signature (REL-17) had an AUC of 0.917 with an optimal sensitivity and specificity of 87% and 83% respectively (Figure S3A). Its predictive capability was validated in an independent set of patients (AUC 0.804, Figure S3B), which was a considerable improvement on the FISH-based predictor (AUC 0.69, Figure S2C). When tested in the validation set, adding t(4;14) and gain(1q) status to this GEP model doesn’t statistically improve the predictive capability (likelihood-ratio test p = 0.21). 
15% of patients in the training set were identified as having a more than 60% chance of relapsing within 1 year, and this group had significantly worse PFS and OS (Figure 2A, B). The significant associations with PFS and OS were validated in the test set (Figure 2C, D). The risk groups derived from REL-17 signature were also compared with those derived from EMC92 signature 25 in multivariate analyses for their performance of predicting relapse within 1 year post-HDT, PFS and OS respectively in the independent test set. The results show that the REL-17 signature performs best for predicting relapse within 1 year and PFS (Table 4), although is also associated with OS (Figure 2D). We applied REL-17 signature to a further independent dataset (GSE24080), either as a whole (p value 2.03 x 10-9 and 3.73 x 10-11 for PFS and OS respectively) or in two subsets from separate trials (Figure S4), where its effects on PFS and OS were also validated. 

Mechanisms of gene deregulation
We explored the possible mechanisms underlying the deregulation of the differentially expressed genes by carrying out integrative analyses of GEP, DNA methylation and SNP-mapping array data. Among the top 37 genes expression levels of MSTO1/MSTO2P (on 1q22), RSBN1 (on 1p13.2), EEF1A1 (on 6q14.1) and REEP5 (on 5q22) were positively correlated with copy number changes (Figure S5, p < 0.05). 
We also looked at the correlation between the expression level of these top deregulated genes and the methylation status of their promoter, except for NUDT11 and MAL2, for which there were no corresponding methylation probes. The methylation probes for these genes were all located in CpG dense areas and map to promoters or transcription start site, with their DNA methylation status following a binary distribution (Figure S6A). The expression levels of 9 genes (CTAG1, EPDR1, CTAG2, PKP2, NGFRAP1, LRIG1, NAP1L3, MAF, LRP12) were statistically correlated with the methylation status (p < 0.05). Scatter plots for these genes show a typical “L” pattern indicating that the hyper-methylation status prevents the genes being transcribed, which suggests that promoters DNA methylation is likely to make an important contribution to the transcription of these genes (Figure S6B). As MAF has been shown to be deregulated via t(14;16) and can also be induced via WHSC1 translocation, the correlation for MAF was only analysed in cases negative for both t(14;16) and t(4;14) by FISH and a correlation with methylation status was seen. For the genes that are located on chromosome X, the correlations were also confirmed in each gender group separately (data not shown). 

DISCUSSION
MM therapeutic schemes are changing rapidly with the constant introduction of new drugs. Although a few studies showed that regimens containing novel agents alone produce comparable response rate as those of HDT, prospective data based on a head-to-head comparison is limited, especially for the long-term effect. A study (ASCO 2013 abstract #2509) comparing melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan (HDM) and autologous transplantation in newly diagnosed myeloma showed that HDM significantly prolonged PFS in comparison with MPR, while 4-year OS rate is similar.  Obviously longer follow-up is required to conclude the long-term effect on OS. Therefore, novel agents are integrated into HDT procedure being used as a part of induction or maintenance rather than replacing HDT as the first-line regimen. These agents are now incorporated prior to and following the transplant procedure, and have resulted in improvements in outcome.
In this work we show that one of the most significant predictors for long term survival following HDT-ASCT at presentation is the time to first relapse.  Our analyses show a clear differential effect on post-relapse survival between patients who relapse within 1 year in contrast to those relapsing later.  We used this observation as a tool to derive a GEP-based predictor for outcome that effectively identifies cases at high risk of early relapse. When tested in the training set, cases considered as being at high risk, having a > 60% probability of early relapse, were shown to have significantly shorter PFS and OS compared to the rest of the cases. The effects on both OS and PFS was validated in two independent datasets, interestingly the prognostic merit of this predictor was also seen in the TT3 cohort, which comprises the most intensively-treated cases so far (bortezomib/thalidomide-combined induction followed by double autograft with bortezomib/lenalidomide-combined maintenance)  ADDIN EN.CITE 26. Therefore this signature seems to be applicable for all cases receiving HDT-ASCT regardless of the type of induction and maintenance therapy received.  
We show that the presence of known FISH-based abnormalities, including adverse IgH translocations and gain(1q), are strongly associated with early relapse following HDT. However, in our analysis this FISH-based predictor only has a modest predictive performance, therefore, lacks the sensitivity and specificity to be used as a prognostic test. Furthermore these FISH abnormalities do not statistically improve the predictive capability of the REL-17 signature for high risk clinical behaviour. This is consistent with observations from the EMC92 25 and UAMS  ADDIN EN.CITE 14 signatures suggesting that additional biological features, defined by the GEP, interact with behaviour induced by the FISH variables to determine high risk behaviour. As the number of genes comprising this signature is low and the risk score is calculated based on the binary expression status of each gene (high/low), it could be transformed into an RT-PCR-based test. 
Among the 37 genes most differentially expressed between the two risk groups, the expression of FGFR3, WHSC1 and DSG2 are known to be deregulated via t(4;14). The association of t(4;14) myeloma with aggressive relapse has been reported in a number of studies  ADDIN EN.CITE 27-28. These genes, together with another four significantly deregulated genes NGFRAP1, NAP1L3, TEAD1, LRP12, AGAP1 (CENTG2), are among the overexpressed genes previously seen within this molecular subgroup  ADDIN EN.CITE [23]. MAF, another gene associated with early relapse, is a transcriptional activator of key target genes and is mainly deregulated via t(14;16)  ADDIN EN.CITE 29. 
Gene enrichment analysis by chromosome location shows that the 207 deregulated genes (FDR < 0.05) were significantly overrepresented on chromosome 1 and X; notably the overrepresentation of genes on chromosome 1 was no longer seen among the top 37 deregulated genes (FDR < 0). These findings support the importance of genes in the 1q12-q23 region as being important outcome predictors, but also that there are other genes playing more important roles in determining high risk behaviour, which are not able to be identified by FISH approach. Despite the over-representation of genes from chromosome X, the risk of early relapse was not associated with gender (data not shown). Among the genes located on chromosome X CTAG1, CTAG2 and MAGEB2 belong to cancer testis gene family (CTAGs), which have been previously demonstrated to have prognostic value in myeloma patients  ADDIN EN.CITE 30. It is also noteworthy that the 37 top deregulated genes were enriched for myeloma “stem cell” gene set 23 including NUDT11, PKP2, ROBO1, AGAP1, NAP1L3 and EPDR1, indicating that “stemness” may play an  important role in determining high risk behaviour. It is interesting that, one of these genes, ROBO1, together with another deregulated gene HMGN5, is also present in the UAMS 70-gene signature  ADDIN EN.CITE 14. 
Integrative analysis of GEP and SNP-mapping array data shows that only four of the 37 top differentially expressed genes were possibly deregulated via copy number variation. Two of them were located on 1q22 and 1p13.2 respectively, which may reflect the association of gain(1q) and del(1p) with inferior outcome. The majority of the top differentially expressed genes did not appear to be deregulated via mechanisms which could be detected by FISH such as translocations or gains/losses. The exploratory analysis integrating GEP and DNA-methylation profiling shows that 9 of these genes were statistically associated with the DNA methylation level at the promoter, suggesting an epigenetic mechanism being involved in their transcription, among which CTAG genes have been previously shown to be silenced by DNA methylation during normal cellular differentiation  ADDIN EN.CITE 31. We also found significant evidence showing three “stem cell” genes PKP2, NAP1L3 and EPDR1 might be modulated via DNA methylation.  Although MAF is normally deregulated via t(14;16) and t(4;14) in MM, there are still cases that express this gene while lack these translocations, consistent with additional unknown mechanisms driving its transcription. In this analysis the association between MAF expression and the promoter methylation status suggests a possible epigenetic mechanism in its transcription, as is frequently seen in diffuse large B-cell lymphomas  ADDIN EN.CITE 32. 
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Table 1. The associations of clinical and FISH parameters with early relapse were evaluated in 718 patients from Myeloma IX trial. Hb, Plt, adverse IgH translocations (including t(4;14), t(14;16) and t(14;20)) and gain(1q) were significantly associated with early relapse in univariate analyses; however, only adverse IgH translocations and gain(1q) remain significant in a multivariate analysis which was performed in 348 patients with completed dataset on these variables.


Predictive factors at diagnosis	Univariate	Multivariate









Table 2. Top 37 deregulated genes at FDR 0, among which 30 were upregulated (A) while 7 were downregulated (B) in early relapse cases in training set. Seventeen of these genes were retained in the final optimized predictor for early relapse (highlighted in bold).

A.
Gene ID	Gene Symbol	Score(d)	Fold Change	Cytoband	GO-term/Description
210546_x_at	CTAG1A /// CTAG1B	-4.92	0.54	Xq28	cancer testis antigen 1
223253_at	EPDR1	-4.71	0.46	7p14.1	cell-matrix adhesion
215733_x_at	CTAG2	-4.69	0.48	Xq28	cancer testis antigen 2
219895_at	FAM70A	-4.17	0.31	Xq24	-
207717_s_at	PKP2	-4.09	0.40	12p11	cell adhesion
207307_at	HTR2C	-4.02	0.51	Xq24	cGMP biosynthetic process, signal transduction, response to drug
217963_s_at	NGFRAP1	-3.82	0.41	Xq22.2	apoptosis
211596_s_at	LRIG1	-3.80	0.54	3p14	DNA replication, DNA repair
201037_at	PFKP	-3.75	0.66	10p15.3-p15.2	protein homotetramerization
204379_s_at	FGFR3	-3.75	0.22	4p16.3	signal transduction, cell proliferation, cell differentiation
204749_at	NAP1L3	-3.68	0.58	Xq21.3-q22	nucleosome assembly
204066_s_at	AGAP1	-3.66	0.51	2q37	signal transduction, protein transport
217975_at	WBP5	-3.64	0.48	Xq22.2	mediating protein-protein interactions




219855_at	NUDT11	-3.50	0.63	Xp11.22	vesicle trafficking, DNA repair
201387_s_at	UCHL1	-3.49	0.40	4p14	protein deubiquitination /// negative regulation of MAP kinase activity
224650_at	MAL2	-3.48	0.54	8q23	protein transport
222778_s_at	WHSC1	-3.46	0.54	4p16.3	chromatin modification /// regulation of transcription
59697_at	RAB15	-3.45	0.66	14q23.3	protein transport, signal transduction
208180_s_at	HIST1H4H	-3.39	0.57	6p21.3	nucleosome assembly
202345_s_at	FABP5	-3.35	0.51	8q21.13	lipid metabolic process /// transport
224233_s_at	MSTO1 /// MSTO2P	-3.34	0.72	1q22	mitochondrion organization, protein polymerization
206218_at	MAGEB2	-3.31	0.62	Xp21.3	melanoma antigen family B2
221606_s_at	HMGN5	-3.28	0.59	Xq13.3	regulation of transcription /// chromatin modification
206363_at	MAF	-3.24	0.47	16q22-q23	cytokine production /// regulation of transcription





























































Table 4. The risk groups derived from the 17-gene early relapse signature (REL-17) were compared with those derived from EMC-92 signature in multivariate analyses for their performance predicting (A) relapsing within 1 year, (B) PFS and (C) OS in the test set (N=155).
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Figure 1. The impact of remission duration on post-relapse survival according to data from Myeloma IX. (A) The analyses on 423 relapsed cases show a cut-off effect of relapsing within 1 year on post-relapse survival: median 4.1 months (< 6 months), 16.1 months (6 months -1 yr), 40 months (1 yr-18 months), 33.4 months (18 months-2 yrs) and not reached (>2 yrs); (B) When combined, patients who relapsed within 1 year post-HDT had median post-relapse survival of 14.9 months in contrast to 40 months with those who relapsed at later point (Log-rank test p = 8.03 x10-14).

Figure 2. The effect of the risk groups derived from the REL-17 signature on PFS and OS. In the training set 15.1% cases being identified as having more than 60% chance to relapse within 1 year had significantly shorter PFS (Figure A; median 13.8 vs 34.8 months, p < 10-16) and OS (Figure B; median 29.9 vs 88.1 months, p = 2.39 x 10-14) in contrast to those at lower risk. Using the same criteria 12.3% patients being identified at high risk in the test set also had significantly shorter PFS (Figure C; median 15.9 vs 40.5 months, p =10-7) and OS (Figure D; median 53 months vs not reached, p =0.0003) compared to rest of the cases.

Figure S1. A diagram showing the analysis flow in this study including samples used and treatment schedule (A) Myeloma IX intensive arm was used to define high risk group and associated clinical/FISH parameters (B) GEPs derived from Myeloma IX, HOVON 65 and GMMG-HD3/HD4 were assigned to training and validation sets for development of 17-REL signature 

Figure S2. Optimized predictor for early relapse (< 1y post-HDT) based on the status of adverse IgH translocations and gain(1q) in (A) Myeloma IX complete set (N=718); (B) expression training set (N=179); (C) expression test set (N= 155).

Figure S3. Performance of the early-relapse predictor. (A) ROC curve of the early-relapse predictor showing the optimal sensitivity and specificity of 87% and 83% respectively in the training set (N=179). (B) The predictor has been validated in an independent test set (N=155).

Figure S4. The associations of the early-relapse signature with (A) PFS and (B) OS were validated in a further dataset (GSE24080), which were also consistent in the two subsets TT2 (C, D) and TT3 (E, F).

Figure S5. The correlation analyses of gene expression level and their copy numbers. Among the 37 deregulaed genes only the expression levels of MSTO1/MSTO2P (on 1q22), RSBN1 (on 1p13.2), EEF1A1 (on 6q14.1) and REEP5 (on 5q22) were shown to be copy number sensitive.

Figure S6. The association between gene expression levels and the DNA-methylation levels at the promoter. (A) An example of density plot showing the cut-off for hyper- and hypo- methylation defined by k-means method; (B) Examples showing the correlation of high/low DNA methylation and the expression levels of three genes LRIG1, PKP2 and NAP1L3


z=-1.2153 + 210546_x_at(H)*0.5535 + 223253_at(H)*0.371 + 219895_at(H)*1.588 + 207717_s_at(H)*0.8155 + 204379_s_at(H)*0.423 + 213194_at(H)*0.835 + 226112_at(H)*0.7029 + 219855_at(H)*0.3427 + 224650_at(H)*0.4121 + 59697_at(H)*0.1446 + 206218_at(H)*0.1698 + 206363_at (H)*0.1265 + 218597_s_at(H)*1.9405 - 242388_x_at(H)*0.979 - 222790_s_at(H)*0.8829 - 227708_at(H)*0.8721 -  208873_s_at(H)*1.3275
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